1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, ...
1. Apatinib plus pegylated liposomal doxorubicin led to longer overall survival and progression-free survival, and a higher objective response rate ...
1. The median progression-free survival for trametinib was significantly greater than that for standard-of-care therapy (13 months vs. 7.2 months). ...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
Image: PD 1. Combining bevacizumab with standard chemotherapy improved progression free survival and objective response rate in platinum-resistant ovarian cancer. ...
